4 Ethical Principles
Clinical research asks people to accept risks and inconveniences not primarily for their own benefit, but so that future patients might have better treatments. This arrangement requires an ethical foundation that respects the dignity and welfare of every research participant.
Research ethics emerged largely in response to abuse. The Nuremberg Code responded to Nazi atrocities. The Declaration of Helsinki was developed by physicians seeking to self-regulate (and was most recently updated in October 2024) (World Medical Association 2024). The Belmont Report followed revelations of the Tuskegee Syphilis Study.
But ethical research is not merely the absence of abuse. It requires affirmative principles that guide researchers toward conduct that is not just permissible, but genuinely ethical.
For many people, “ethical research” is synonymous with “informed consent.” Certainly, consent is essential—but ethicists have long recognized that it is not sufficient. A scientifically worthless study remains unethical even if every participant provides exquisitely informed consent, because it exposes people to risks without any possibility of generating knowledge that could benefit others (Emanuel, Wendler, and Grady 2000).
4.1 Seven Requirements for Ethical Research
Emanuel, Wendler, and Grady proposed a comprehensive framework of seven requirements (Table 4.1) that clinical research must satisfy to be considered ethical (Emanuel, Wendler, and Grady 2000):
| Requirement | Ethical Principle | Key Question | Example Application |
|---|---|---|---|
| 1. Value | Research must have social or scientific value | Will this research improve health or increase understanding? | A study duplicating existing knowledge is unethical regardless of consent, as it exposes participants to risk without potential benefit. |
| 2. Scientific Validity | Research must be methodologically rigorous | Is the study designed to answer its research question? | Underpowered studies that cannot detect meaningful effects cannot justify participant risks. |
| 3. Fair Subject Selection | Burdens and benefits should be distributed fairly | Are subjects chosen for scientific reasons, not convenience or vulnerability? | Testing drugs only in young men while marketing to all populations violates this principle. |
| 4. Favorable Risk-Benefit Ratio | Risks must be justified by potential benefits | Do potential benefits outweigh risks to participants and society? | High-risk procedures require proportionately important research questions. |
| 5. Independent Review | Conflicts of interest must be managed through oversight | Has the research been reviewed by unaffiliated experts? | IRB approval is mandatory; investigators cannot approve their own studies. |
| 6. Informed Consent | Participants must voluntarily agree with understanding | Do participants understand and freely agree? | Consent forms must be readable; participants can withdraw at any time. |
| 7. Respect for Participants | Researchers have ongoing responsibilities | Are participants’ interests protected throughout and after the study? | Privacy must be maintained; participants should be informed of new findings. |
These seven requirements go beyond informed consent alone. A study can obtain perfect consent yet still be unethical if it lacks value, scientific validity, or fair subject selection. All seven requirements must be satisfied.
4.2 Applying Ethical Principles
Placebo Controls
One of the most contentious issues in research ethics is the use of placebo controls when effective treatments exist. On one hand, placebo-controlled trials often provide the clearest evidence of efficacy. On the other hand, they may involve withholding known-effective treatment from patients who need it.
The Declaration of Helsinki takes a strong position: new interventions should generally be tested against the best current proven intervention, not against placebo. However, placebo controls may be acceptable when no proven intervention exists, when compelling methodological reasons require a placebo comparison, when participants will not be subject to serious or irreversible harm, and when participants are fully informed.
This remains an area of active ethical debate, particularly for conditions where treatments exist but are imperfect.
Vulnerable Populations
Certain populations require additional protections in research (U.S. Department of Health and Human Services 2024). The key vulnerable populations and their specific considerations are summarized in Table 4.2:
| Population | Specific Vulnerability | Additional Protections Required | Ethical Consideration |
|---|---|---|---|
| Children | Cannot provide legal consent; may not understand research | Parental/guardian permission plus child assent when capable | Risks must be justified by direct benefit or minimal risk with generalizable knowledge |
| Pregnant Women | Risks extend to fetus | Preclinical and clinical data on pregnancy risks required | Research must minimize risk to fetus; consent must address fetal risks |
| Prisoners | Institutional coercion may compromise voluntariness | Research limited to conditions affecting prisoners or criminal justice system | Payment and conditions must not be coercive |
| Cognitively Impaired | Reduced capacity for informed consent | Legally authorized representative consent; subject assent when possible | Ongoing assessment of capacity; respect for objection even if representative consented |
| Economically Disadvantaged | Payment may be unduly influential | Compensation must not be coercive | Payment for time/inconvenience appropriate; payment contingent on completion is not |
The ethical approach is not to exclude vulnerable populations from research—they too deserve therapies developed and tested in relevant populations—but to implement additional safeguards appropriate to the specific vulnerabilities involved (Emanuel, Wendler, and Grady 2000).
Research in Resource-Limited Settings
These questions have no universal answers, but they demand thoughtful engagement. Researchers must navigate whether control groups should receive the best available global treatment or the local standard of care, while establishing clear plans for post-study access to beneficial interventions. Ethical research requires ensuring that clinical studies do not merely exploit resource-limited communities for data but instead provide tangible health benefits and long-term improvements to the host population.
4.3 Modern Ethical Challenges
The digital transformation of clinical trials has introduced new ethical concerns.
eConsent and digital literacy present a tension: electronic informed consent offers multimedia tools (videos, quizzes) to improve understanding, but creates barriers for populations with lower digital literacy. Ethical practice requires ensuring that modernizing consent does not inadvertently exclude those uncomfortable with technology.
Data privacy in decentralized trials poses new risks. With the rise of DCTs, patient data is collected continuously via wearables and smartphone apps. This granular data (GPS location, sleep patterns) carries re-identification and “function creep” risks (data collected for one purpose becoming useful for another). Researchers must balance the scientific value of high-frequency data with the participant’s right to digital privacy (World Health Organization 2021).
Electronic informed consent (eConsent): documentation, comprehension, and equity
Electronic informed consent is now widely used in clinical investigations, but ethical acceptability depends on more than digitizing signatures. The ethical standard remains comprehension and voluntariness, while the operational standard extends to reliable documentation, auditability, and appropriate protections for privacy and participant autonomy (Emanuel, Wendler, and Grady 2000; U.S. Food and Drug Administration 2016, 2024b).
In decentralized or hybrid trials, remote consent can reduce travel burden and broaden access, but it also increases the risk that participants with lower digital literacy, limited broadband access, or limited accessibility accommodations are systematically excluded. From an ethics perspective, this is a fair subject selection concern: an operational convenience can become a structural enrollment bias unless alternative pathways are offered (Emanuel, Wendler, and Grady 2000; U.S. Food and Drug Administration 2024a).
- Use plain-language explanations and layered disclosure (short summary plus details), and verify comprehension (e.g., teach-back or comprehension checks) rather than relying on “click-through” completion alone (U.S. Food and Drug Administration 2016).
- Provide equivalent non-digital pathways (paper or staff-assisted workflows) to avoid excluding participants who cannot or prefer not to use digital tools (Emanuel, Wendler, and Grady 2000).
- Specify identity verification, version control of consent content, and procedures for re-consent when new information emerges (U.S. Food and Drug Administration 2016).
- Ensure documentation and auditability are suitable for regulated electronic records and signatures (e.g., validated systems, audit trails, access control, retention) (U.S. Food and Drug Administration 2023a, 2024b).
- Define privacy-by-design boundaries for any data collected during consent (device identifiers, contact methods, metadata) and ensure participants understand what is collected and why (World Health Organization 2021).
AI and automation in clinical research ethics
AI systems can support ethical goals (e.g., earlier detection of safety signals, better protocol feasibility, lower site burden), but they can also undermine them if they amplify bias, reduce participant understanding, or shift accountability in ways that are hard to justify. The ethical question is rarely “is AI allowed?”; it is whether its use satisfies the same seven requirements that make any study ethical (Emanuel, Wendler, and Grady 2000).
Fair subject selection and justice. Recruitment algorithms trained on historical site performance, claims, or EHR data can reproduce inequities—systematically under-identifying eligible participants in under-resourced health systems or under-represented groups. Bias auditing should therefore be treated as an ethical safeguard, not an optional “model improvement” step (World Health Organization 2021; Saleiro et al. 2018). Documentation artifacts such as dataset “datasheets” and model “cards” help make these limitations explicit to reviewers and users (Gebru et al. 2021; Mitchell et al. 2019).
Informed consent and understanding. If AI influences eligibility triage, monitoring intensity, or what a coordinator asks a participant to do (e.g., app-based prompts), then “what participants are consenting to” includes the role of automated systems. There is a risk that fluent, confident outputs create an illusion of understanding—among staff and participants—without reliable grounding in the source record or the evidence base (Messeri and Crockett 2024; Bender et al. 2021). Ethical practice therefore requires transparency about what is automated, what is reviewed by humans, and what can be corrected.
Respect for participants (privacy, dignity, and autonomy). Continuous sensing and “always-on” monitoring can feel intrusive even when clinically informative. Ethical review should explicitly consider minimization (collect only what is necessary), proportionality (match intrusiveness to expected value), and participant control (pause/opt-out mechanisms) (World Health Organization 2021).
Accountability and governance. Ethical acceptability also depends on clear responsibility: who is answerable when an algorithm misclassifies, misses a safety signal, or increases burden for a subgroup? Professional bodies emphasize that AI should augment—not replace—clinician and researcher judgment and that accountability remains human (World Medical Association 2024; European Medicines Agency 2024). Practical governance can be structured using risk management concepts (intended use, hazards, controls, monitoring) rather than marketing claims (National Institute of Standards and Technology 2023; Amershi et al. 2019).
4.4 The IRB in Practice
The IRB is the primary institutional mechanism for ethical oversight (Table 4.3) (U.S. Food and Drug Administration 2023b):
| Review Type | Timing | Purpose | IRB Action |
|---|---|---|---|
| Initial Review | Before research begins | Evaluate protocol for ethical compliance | Approve, require modifications, or disapprove research |
| Continuing Review | At least annually during study | Verify ongoing compliance and assess new information | Reapprove, require changes, suspend, or terminate |
| Modification Review | When protocol/consent changes proposed | Evaluate impact of changes on risk-benefit | Approve or disapprove modifications |
| Adverse Event Review | When serious/unexpected events occur | Assess whether study can continue safely | May require protocol changes, additional monitoring, or suspension |
| Final Review | At study completion | Close out study oversight | Document study completion and any findings |
The IRB’s authority is not advisory—it is decisive. Research cannot proceed without IRB approval. Except for changes necessary to eliminate immediate hazards, all modifications must be approved before implementation.